More Surprises Stem from RV144

Jill Kresge, Kristen
September 2011
VAX;Sep2011, Vol. 9 Issue 5, p1
The article reports that the RV144 vaccine has provided evidence of vaccine-induced protection against human immunodeficiency virus. As stated, various other clinical trials are undergoing in order to see whether vaccines like VAX003 and 004 also have same immune responses to the prime-boost regimen as the vaccine RV144 had. As further stated, some researchers are conducting trials using monkeys to analyze the effect of antibodies in prevention of infection among monkeys. INSET: ALSO IN THIS ISSUE.


Related Articles

  • A booster for HIV vaccine research. Quan, Andy // HIV Australia;Dec2003-Feb2004, Vol. 3 Issue 2, p8 

    Highlights the issues discussed at the Aids Vaccine 2003 annual conference in New York City from September 18 to 21, 2003. Announcement of vaccine products that will enter a large clinical trial; Funding provided by the Gates Foundation for the Global Vaccine Enterprise, which aims to provide...

  • Understanding the Rationale for Combination Prevention Trials. McEnery, Regina // VAX;Sep2011, Vol. 9 Issue 5, p4 

    The article reports that various methods including adult male circumcision, pre-exposure prophylaxis (PrEP), and vaccination have succeeded in preventing human immunodeficiency virus. As stated, all these methods are partially effective and researchers are working towards development of...

  • One Oral PrEP Arm Discontinued Early in VOICE Trial.  // VAX;Sep2011, Vol. 9 Issue 5, p3 

    The article reports that the clinical trial titled VOICE that was scheduled to be concluded in June 2012 was terminated in September 2011. As stated, the termination was declared when it was examined that the trial would not be able to highlight any difference between daily doses of...

  • HIV vaccine: Sell-out or vote of confidence by Genentech? Wadman, Meredith // Nature;2/29/1996, Vol. 379 Issue 6568, p757 

    Reports that Genentech Inc. of South San Francisco, California, is creating a new company, Genenvax Inc., to try to bring an HIV vaccine they have been developing, the gp120, to market. Concern that clinical trials in the United States and Thailand will risk infection with HIV in the mistaken...

  • The Search for a Vaccine.  // Access;Nov2001, Vol. 15 Issue 9, p46 

    Discusses the major obstacles in the development of AIDS vaccine. Accounts of clinical trials of AIDSVAX, an AIDS vaccine candidate, with human subjects; Effects of public perception on AIDS on the development of AIDS vaccine; Problem in the lack of coordination among research organizations...

  • Reasons for Declining to Enroll in a Phase I and II HIV Vaccine Trial after Randomization among Eligible Volunteers in Dar es Salaam, Tanzania. Tarimo, Edith A. M.; Thorson, Anna; Kohi, Thecla W.; Bakari, Muhammad; Mhalu, Fred; Kulane, Asli // PLoS Clinical Trials;Feb2011, Vol. 8 Issue 2, Special section p1 

    Background: Recruitment, enrollment and retention of volunteers in an HIV vaccine trial is important in the efforts to ultimately develop a vaccine that can prevent new HIV infections. Following recruitment, some randomized individuals decline to be enrolled in an HIV vaccine trial. The reasons...

  • Rhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge. Eugene, Hermancia S.; Pierce-Paul, Brooke R.; Cragio, Jodi K.; Ross, Ted M. // Virology Journal;2013, Vol. 10 Issue 1, Special section p1 

    The development of a preventative HIV/AIDS vaccine is challenging due to the diversity of viral genome sequences, especially in the viral envelope (Env160). Since it is not possible to directly match the vaccine strain to the vast number of circulating HIV-1 strains, it is necessary to develop...

  • Coping with Viral Diversity in HIV Vaccine Design. Nickle, David C.; Rolland, Morgane; Jensen, Mark A.; Kosakovsky Pond, Sergei L.; Wenjie Deng; Seligman, Mark; Heckerman, David; Mullins, James I; Jojic, Nebojsa // PLoS Computational Biology;Apr2007, Vol. 3 Issue 4, pe75 

    The ability of human immunodeficiency virus type 1 (HIV-1) to develop high levels of genetic diversity, and thereby acquire mutations to escape immune pressures, contributes to the difficulties in producing a vaccine. Possibly no single HIV-1 sequence can induce sufficiently broad immunity to...

  • Vaccines: HIV vaccine failure due to induction of immune suppressors? Flemming, Alexandra // Nature Reviews Drug Discovery;Aug2014, Vol. 13 Issue 8, p574 

    The article focuses on the finding of a study which shows that an anti-HIV vaccines can induce suppressor cells and thereby dampen any specific immune responses. The use of a peptide-prime/modified vaccinia Ankara (MVA) boost vaccine with Toll-like receptor 2 antagonists to explore the potential...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics